Management of Suspected Ovarian Masses in Premenopausal Women

Background

In premenopausal women, almost all ovarian masses are benign. The risk of malignancy in a symptomatic cyst is approximately 1:1000, rising to 3:1000 by age 50. Around 10% of suspected "ovarian" masses are ultimately non-ovarian in origin (e.g. paratubal cyst, hydrosalpinx, tubo-ovarian abscess, pelvic kidney). No single test or algorithm reliably distinguishes benign from malignant disease preoperatively, except germ cell tumours, which are flagged by elevated tumour markers.

Assessment: History, Examination and Tumour Markers

• Take a history focused on malignancy red flags (persistent bloating, early satiety, pelvic/abdominal pain, urinary urgency/frequency) and endometriosis symptoms; clinical examination has poor sensitivity (15–51%) but helps assess tenderness, mobility, nodularity and ascites.
• CA-125 is not required when ultrasound has already made a clear diagnosis of a simple cyst (Grade B). Its use in premenopausal women is limited by poor specificity: it is commonly raised by fibroids, endometriosis, adenomyosis and pelvic infection, and is a marker of epithelial ovarian cancer only — it is elevated in just 50% of early-stage epithelial disease. Only severe (stage III–IV) endometriosis typically raises CA-125 into the hundreds-to-thousands range.
  • If CA-125 is raised but <200 IU/ml, investigate other differentials first.
  • If CA-125 is >200 IU/ml, discuss with a gynaecological oncologist.
  • Serial, rising CA-125 is more suggestive of malignancy than a single static high value.
• LDH, AFP and hCG should be measured in all women under 40 with a complex ovarian mass (Grade C) because of the possibility of a germ cell tumour.

Imaging and Risk Stratification

Transvaginal ultrasound is the single most effective imaging modality (Grade B); routine CT/MRI adds no sensitivity or specificity over TVS (Grade C).

Two risk-stratification approaches are endorsed:

• Risk of Malignancy Index (RMI I) = Ultrasound score (U) × Menopausal status (M) × serum CA-125 (IU/ml). U=0 for no suspicious features, U=1 for one feature, U=3 for two or more (from: multilocular cyst, solid areas, metastases, ascites, bilateral lesions); M=1 premenopausal, M=3 postmenopausal. A pooled cutoff of RMI ≥200 gives sensitivity 78% and specificity 87%, but RMI accuracy is reduced in premenopausal women because endometriomas and borderline tumours often raise CA-125 without malignancy.
• IOTA Simple Rules classify masses using ultrasound features alone (no CA-125 required) into benign (B-rules: unilocular, solid component <7mm, acoustic shadowing, smooth multilocular tumour <100mm, no blood flow) or malignant (M-rules: irregular solid tumour, ascites, ≥4 papillary structures, irregular multilocular-solid tumour ≥100mm, very strong blood flow), with reported sensitivity 95%/specificity 91%. Masses not clearly classifiable need specialist review.

Conservative vs Surgical Management

• Simple cysts <50mm: no follow-up needed — almost always physiological, resolving within 3 menstrual cycles.
• Simple cysts 50–70mm: yearly ultrasound follow-up.
• Simple cysts >70mm: consider MRI or surgical intervention.
• The combined oral contraceptive pill does not accelerate resolution of functional cysts (Grade A).
• Persistent or enlarging cysts are unlikely to be functional and generally warrant surgery, though there is no agreed evidence-based size cutoff (most studies used 50–60mm as an arbitrary ceiling for conservative management).
• Laparoscopy is the preferred surgical approach for presumed-benign masses (Grade A) — lower morbidity, faster recovery, more cost-effective than laparotomy. Laparotomy/mini-laparotomy may suit very large masses with solid components (e.g. large dermoids); cyst rupture during laparoscopy is more common above ~70mm.
• Needle aspiration is discouraged — high recurrence (53–84%) (Grade B).
• Spillage of cyst contents should be avoided (use a retrieval bag); specimen removal via the umbilical port is preferred over lateral ports (Grade A).

High-Yield Exam Points

• CA-125 is not routinely needed for a simple cyst on ultrasound — a classic distractor trap.
• CA-125 is unreliable in premenopausal women due to false positives from fibroids/endometriosis/PID/adenomyosis; it detects only ~50% of early-stage epithelial cancers.
• CA-125 >200 IU/ml → discuss with gynaecological oncology.
• Under-40s with a complex mass → check AFP, hCG, and LDH (germ cell tumour markers).
• RMI I = U × M × CA-125; cutoff ≥200 (sensitivity 78%, specificity 87%), but less reliable in premenopausal women.
• IOTA Simple Rules can risk-stratify without CA-125.
• Simple cyst thresholds: <50mm no follow-up, 50–70mm yearly scan, >70mm consider MRI/surgery.
• Laparoscopy is the gold-standard surgical approach for presumed-benign masses; aspiration is not recommended due to high recurrence.

Source: RCOG Green-top Guideline No. 62 (November 2011 (first edition, joint RCOG/BSGE guideline; the RCOG lists a second edition as in development))

Read the original on rcog.org.uk

Clinically reviewed by NHS obstetricians and gynaecologists · Source last updated November 2011 (first edition, joint RCOG/BSGE guideline; the RCOG lists a second edition as in development)

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).